|
|
 |
 |
| |
 Printable version |
Antihormonal therapy in breast cancer and mTOR inhibitors |
Bulletin du Cancer. Volume 98, Number 12, 1431-7, December 2011, Synthèse
|
 Résumé
Texte intégral
|
Author(s) : Pierre-Étienne Heudel, Olivier Tredan, Isabelle Ray-Coquard, Isabelle Treilleux, Jean-Paul Guastalla, Thomas Bachelot |
Summary : Hormonal dependence of breast cancer has been known for a long time, yet about half of breast cancers with estrogen receptor will not respond to antihormonal therapy. Now, we know that this resistance may be related to a dysfunction of the estrogen pathway, or that of growth factors and particularly the pathway of cell activation PI3K/Akt/mTOR. Prevention of these different mechanisms of resistance could involve combination therapies such as anti-estrogens (SERMs, aromatase inhibitors) with inhibitors of the activity of growth factors that are particularly temsirolimus and everolimus for the activation pathway cell PI3K/Akt/mTOR. |
Keywords : metastatic breast cancer, hormonotherapy, mTOR inhibitors |
|
